Clinical Trials

In addition to the advances we have made in basic science and translational research, the Dean McGee Eye Institute remains at the forefront of clinical medicine through our Clinical Trials initiative. Here at the institute, our physicians are investigating the latest in drug development and treatment strategies for a number of eye conditions. These studies are funded by the National Eye Institute (NEI) and pharmaceutical industry.

Clinical trials are an essential step to foster the best in patient care while also offering patients the most modern, cutting edge treatment. Patients choose to participate in clinical trials for many reasons; they may have the opportunity to receive treatments with tremendous promise but are unavailable outside of a trial, or some simply appreciate the intrinsic feeling of contributing to the advancement of science.

See below for the current list of clinical trials at the Dean McGee Eye Institute in a wide variety of ophthalmology services.

Additional information for all studies can be found on


Study Name: Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR (TRITON)
Condition(s) under Study: Open-angle Glaucoma or Ocular Hypertension
Sponsor: Allergan
Study Summary: To compare the effectiveness of either 10 µg or 15 µg Bimatoprost SR in patients with Open-angle glaucoma or Ocular Hypertension who are not adequately managed with topical medications.
Investigator(s): Dr. Mahmoud Khaimi Information: NCT03850782

Study Name: Condition(s) under Study: XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway (GPS)
Condition(s) under Study: Glaucoma
Sponsor: Allergan
Study Summary: Phase IV open-label clinical trial to evaluate the ability of XEN to reduce IOP and reduce the amount of topical IOP-lowering medications in subjects poorly controlled on topical therapy.
Investigator(s): Dr. Ben Harvey Information: NCT03654885


Study Name: Cerebrotendinous Xanthomatosis Prevalence Study
Condition(s) under Study: Cerebrotendinous Xanthomatosis (CTX)
Sponsor: Retrophin, Inc.
Study Summary: Observational study to determine the prevalence of CTX in patients diagnosed with early-onset bilateral cataracts
Investigator(s): Dr. Maria Lim Information: NCT02638220


Study Name: Genes in Diabetic Retinopathy Project
Condition(s) under Study: Diabetic eye conditions
Sponsor: Diabetic Retinopathy Clinical Research Network
Study Summary: A one time, blood sample collection study looking at genetic susceptibility and resistance to Diabetic Retinopathy and other variants impacting visually-important biomarkers for macular edema and neovascularization.
Investigator(s): Dr. Ronald Kingsley Information: None available.

Studay Name: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy 
Conditions(s) under Study: Dry age-related macular degeneration with geographic atrophy
Sponsor: Stealth BioTherapeutics Inc.
Study Summary: Daily subcutaneous elamipretide through the elamipretide delivery system for 12 months.
Investigator(s): Dr. Sun Young Lee (Principal Investigator), Dr. Ronald Kingsley (Sub-PI) Information: NCT03891875